By receptors, binding sites or free radical scavenger action: Is there a pivotal action mechanism for melatonin in retinal pathologies?

New Developments in Melatonin Research

Volumn , Issue , 2013, Pages 193-203

  de Fatima Sobral Sampaio, Lucia ^a  

^a Lab Biochemistry of the CNS Development   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84895251731     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (57)

1. Blasic JR, Jr., Lane BR, Robinson PR. Light-dependent phosphorylation of the carboxy tail of mouse melanopsin. Cell Mol. Life Sci. 2012 May; 69(9):1551-62.
2. Contin MA, Verra DM, Guido ME. An invertebrate-like phototransduction cascade mediates light detection in the chicken retinal ganglion cells. FASEB J. 2006 Dec; 20(14):2648-50.
3. Perez-Leighton CE, Schmidt TM, Abramowitz J, Birnbaumer L, Kofuji P. Intrinsic phototransduction persists in melanopsin-expressing ganglion cells lacking diacylglycerol-sensitive TRPC subunits. Eur. J. Neurosci. 2011 Mar; 33(5):856-67.
4. Van Hook MJ, Wong KY, Berson DM. Dopaminergic modulation of ganglion-cell photoreceptors in rat. Eur. J. Neurosci. 2012 Feb; 35(4):507-18.
5. Verra DM, Contin MA, Hicks D, Guido ME. Early onset and differential temporospatial expression of melanopsin isoforms in the developing chicken retina. Invest. Ophthalmol. Vis. Sci. 2011 Jul; 52(8):5111-20.
6. Zele AJ, Feigl B, Smith SS, Markwell EL. The circadian response of intrinsically photosensitive retinal ganglion cells. PLoS One 2011;6(3):e17860.
7. Sand A, Schmidt TM, Kofuji P. Diverse types of ganglion cell photoreceptors in the mammalian retina. Prog. Retin. Eye Res. 2012 Jul; 31(4):287-302.
8. La MC, Ross-Cisneros FN, Sadun AA, Hannibal J, Munarini A, Mantovani V, et al. Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain 2010 Aug;133(Pt 8):2426-38.
9. Perez-Rico C, de , V, Blanco R, Germain F, Paz-Moreno J, Arribas-Gomez I. [Alterations in nocturnal melatonin secretion in patients with optic neuropathies]. Arch. Soc. Esp. Oftalmol. 2009 May; 84(5):251-7.
10. Emens J, Lewy AJ, Laurie AL, Songer JB. Rest-activity cycle and melatonin rhythm in blind free-runners have similar periods. J. Biol. Rhythms 2010 Oct; 25(5):381-4.
11. Dinet V, Ansari N, Torres-Farfan C, Korf HW. Clock gene expression in the retina of melatonin-proficient (C3H) and melatonin-deficient (C57BL) mice. J. Pineal. Res. 2007 Jan; 42(1):83-91.
12. Lucas RJ, Foster RG. Neither functional rod photoreceptors nor rod or cone outer segments are required for the photic inhibition of pineal melatonin. Endocrinology 1999 Apr; 140(4):1520-4.
13. Haque R, Chong NW, Ali F, Chaurasia SS, Sengupta T, Chun E, et al. Melatonin synthesis in retina: cAMP-dependent transcriptional regulation of chicken arylalkylamine N-acetyltransferase by a CRE-like sequence and a TTATT repeat motif in the proximal promoter. J. Neurochem. 2011 Oct; 119(1):6-17.
14. Hardeland R. Melatonin metabolism in the central nervous system. Curr. Neuropharmacol. 2010 Sep; 8(3):168-81.
15. Nowak R, McMillen IC, Redman J, Short RV. The correlation between serum and salivary melatonin concentrations and urinary 6-hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human circadian rhythmicity. Clin. Endocrinol. (Oxf) 1987 Oct; 27(4):445-52.
16. Pang SF, Cheng KM, Allen AE, Tsang CW, Wong CO, Nichols CR. Inherited changes in concentrations of retinal and serum melatonin in the chicken. Gen. Comp. Endocrinol. 1989 Dec; 76(3):427-36.
17. Zmijewski MA, Sweatman TW, Slominski AT. The melatonin-producing system is fully functional in retinal pigment epithelium (ARPE-19). Mol. Cell Endocrinol. 2009 Aug 13307(1-2):211-6.
18. Cecon E, Markus RP. Relevance of the chronobiological and non-chronobiological actions of melatonin for enhancing therapeutic efficacy in neurodegenerative disorders. Recent Pat. Endocr. Metab. Immune Drug Discov. 2011 May; 5(2):91-9.
19. Valenciano AI, Alonso-Gomez AL, Iuvone PM. Regulation of tryptophan hydroxylase activity in Xenopus laevis photoreceptor cells by cyclic AMP. J. Neurochem. 2000 May; 74(5):1961-7.
20. Mondaca M, Hernandez A, Valladares L, Sierralta W, Noseda R, Soto-Moyano R. Involvement of melatonin metabolites in the long-term inhibitory effect of the hormone on rat spinal nociceptive transmission. Pharmacol. Biochem. Behav. 2004 Feb; 77(2):275-9.
21. Voisin P, Cailleau V, Naud N, Cantereau A, Bernard M. Visual photoreceptor subtypes in the chicken retina: melatonin-synthesizing activity and in vitro differentiation. Cell Tissue Res. 2012 Jun; 348(3):417-27.
22. Alarma-Estrany P, Pintor J. Melatonin receptors in the eye: location, second messengers and role in ocular physiology. Pharmacol. Ther. 2007 Mar; 113(3):507-22.
23. Bok D. Retinal researchers have reasons to be optimistic. Retina 2005 Dec;25(8 Suppl):S43.
24. Dubocovich ML. Modulation of [3H]dopamine release from rabbit retina. Fed. Proc. 1984 Sep; 43(12):2714-8.
25. Dufourny L, Levasseur A, Migaud M, Callebaut I, Pontarotti P, Malpaux B, et al. GPR50 is the mammalian ortholog of Mel1c: evidence of rapid evolution in mammals. BMC Evol. Biol. 2008;8:105.
26. Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol. Rev. 2010 Sep; 62(3):343-80.
27. Sengupta A, Baba K, Mazzoni F, Pozdeyev NV, Strettoi E, Iuvone PM, et al. Localization of melatonin receptor 1 in mouse retina and its role in the circadian regulation of the electroretinogram and dopamine levels. PLoS One 2011;6(9):e24483.
28. Wiechmann AF, Sherry DM. Melatonin receptors are anatomically organized to modulate transmission specifically to cone pathways in the retina of Xenopus laevis. J. Comp. Neurol. 2012 Apr 15520(6):1115-27.
29. Baba K, Pozdeyev N, Mazzoni F, Contreras-Alcantara S, Liu C, Kasamatsu M, et al. Melatonin modulates visual function and cell viability in the mouse retina via the MT1 melatonin receptor. Proc. Natl. Acad. Sci. U S A 2009 Sep 1106(35):15043-8.
30. Fu Y, Tang M, Fan Y, Zou H, Sun X, Xu X. Anti-apoptotic effects of melatonin in retinal pigment epithelial cells. Front Biosci. 2012;17:1461-8.
31. Kaur C, Sivakumar V, Foulds WS, Luu CD, Ling EA. Cellular and vascular changes in the retina of neonatal rats after an acute exposure to hypoxia. Invest. Ophthalmol. Vis. Sci. 2009 Nov; 50(11):5364-74.
32. Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP. Role of melatonin in the eye and ocular dysfunctions. Vis. Neurosci. 2006 Nov; 23(6):853-62.
33. Wiechmann AF, Summers JA. Circadian rhythms in the eye: the physiological significance of melatonin receptors in ocular tissues. Prog. Retin. Eye Res. 2008 Mar; 27(2):137-60.
34. Wiechmann AF, Chignell CF, Roberts JE. Influence of dietary melatonin on photoreceptor survival in the rat retina: an ocular toxicity study. Exp. Eye Res. 2008 Feb; 86(2):241-50.
35. Roka F, Brydon L, Waldhoer M, Strosberg AD, Freissmuth M, Jockers R, et al. Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity. Mol. Pharmacol. 1999 Nov; 56(5):1014-24.
36. Masana MI, Witt-Enderby PA, Dubocovich ML. Melatonin differentially modulates the expression and function of the hMT1 and hMT2 melatonin receptors upon prolonged withdrawal. Biochem. Pharmacol. 2003 Mar 165(5):731-9.
37. Sampaio LF. Melatonin inhibitory effect on cAMP accumulation in the chick retina development. Int J Dev Neurosci 2008 May; 26(3-4):277-82.
38. Sampaio LF, Markus RP. Melatonin and the time window for the expression of the alpha8 nicotinic acetylcholine receptor in the membrane of chick retinal cells in culture. Int. J. Dev. Neurosci. 2010 May; 28(3):245-9.
39. Sampaio LF. An unexpected effect of 5-MCA-NAT in chick retinal development. Int. J. Dev. Neurosci. 2009 Oct; 27(6):511-5.
40. Alcantara-Contreras S, Baba K, Tosini G. Removal of melatonin receptor type 1 increases intraocular pressure and retinal ganglion cells death in the mouse. Neurosci. Lett. 2011 Apr 20494(1):61-4.
41. Pandi-Perumal SR, Bahammam AS, Brown GM, Spence DW, Bharti VK, Kaur C, et al. Melatonin Antioxidative Defense: Therapeutical Implications for Aging and Neurodegenerative Processes. Neurotox. Res. 2012 Jun 28.
42. Rodriguez C, Mayo JC, Sainz RM, Antolin I, Herrera F, Martin V, et al. Regulation of antioxidant enzymes: a significant role for melatonin. J. Pineal Res. 2004 Jan; 36(1):1-9.
43. Rosenstein RE, Pandi-Perumal SR, Srinivasan V, Spence DW, Brown GM, Cardinali DP. Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis. J. Pineal Res. 2010 Aug; 49(1):1-13.
44. Rosen R, Hu DN, Perez V, Tai K, Yu GP, Chen M, et al. Urinary 6-sulfatoxymelatonin level in age-related macular degeneration patients. Mol. Vis. 2009;15:1673-9.
45. Hardeland R. Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012 Apr; 3(2):194-225.
46. Johnson LV, Forest DL, Banna CD, Radeke CM, Maloney MA, Hu J, et al. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proc. Natl. Acad. Sci. U S A 2011 Nov 8;108(45):18277-82.
47. Vojnikovic B, Vojnikovic D. Chromotherapy of macular degeneration with transitions lenses and green-yellow medical filters and special programme for psychoorganic disturbances. Coll. Antropol. 2010 Apr;34 Suppl 2:89-93.
48. Banas I, Buntner B, Niebroj T, Ostrowska Z. [Levels of melatonin in serum of patients with retinitis pigmentosa]. Klin. Oczna. 1995 Nov; 97(11-12):321-3.
49. de ZN, Plano SA, Fernandez DC, Lanzani MF, Salido E, Belforte N, et al. Effect of experimental glaucoma on the non-image forming visual system. J. Neurochem. 2011 Jun; 117(5):904-14.
50. Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. Int. J. Clin. Pract. 2007 May; 61(5):835-45.
51. Ramstad K, Loge JH. [Melatonin treatment of a blind child with serious sleep disorders]. Tidsskr Nor Laegeforen 2002 Apr 20122(10):1005-6.
52. Cavallo A. The pineal gland in human beings: relevance to pediatrics. J. Pediatr. 1993 Dec; 123(6):843-51.
53. Ito J, Saijo H, Tanaka H, Tasaki T, Chou K. [Melatonin treatment for sleep-wake disorder--an experience for a severely mental retarded patient with blindness]. No To Hattatsu 1995 Sep; 27(5):401-3.
54. Lapierre O, Dumont M. Melatonin treatment of a non-24-hour sleep-wake cycle in a blind retarded child. Biol Psychiatry 1995 Jul 1538(2):119-22.
55. Palm L, Blennow G, Wetterberg L. Correction of non-24-hour sleep/wake cycle by melatonin in a blind retarded boy. Ann. Neurol. 1991 Mar; 29(3):336-9.
56. Tzischinsky O, Skene D, Epstein R, Lavie P. Circadian rhythms in 6sulphatoxymelatonin and nocturnal sleep in blind children. Chronobiol. Int. 1991;8(3):168-75.
57. Zucconi M, Bruni O. Sleep disorders in children with neurologic diseases. Semin. Pediatr. Neurol. 2001 Dec; 8(4):258-75.